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Deptor is an important protein that belongs to the mTORC1 and mTORC2 complexes, able to interact with mTOR
and to inhibit its kinase activity. As a natural mTOR inhibitor, Deptor is involved in several molecular pathways, such
as cell growth, apoptosis, autophagy and ER stress response. For this reason, Deptor seems to play an important
role in controlling cellular homeostasis. Despite several recent insights characterizing Deptor functions and regulation,
its complete role within cells has not yet been completely clarified. Indeed, quite recently, Deptor has been associated
with chromatin, and it has been demonstrated having a role in transcriptional regulation, controlling in such way
endoplasmatic reticulum activity.
From all these observations it is not surprising that Deptor can behave either as an oncogene or oncosuppressor,
depending on the cell- or tissue-contexts. This review highlights recent progresses made in our understanding of the
many activities of Deptor, describing its transcriptional and post-transcriptional regulation in different cancer cell types.
Moreover, here we discuss the possibility of using compounds able to inhibit Deptor or to disrupt its interaction with
mTOR as novel approaches for cancer therapy.
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Over the last few years, Deptor (DEP-domain containing
mTOR-interacting protein), also known as DEPDC6
(DEP-domain containing protein 6) has become the
focus of relevant studies regarding the development and
progression of human malignancies, due to discovering
its role as a naturally negative regulator of mTOR
(mammalian Target Of Rapamicin) [1]. In fact, this
protein is an important component of the mTORC1 and
mTORC2 complexes and interacts with mTOR, thereby
inhibiting its kinase activity [2]. In addition, Deptor and
mTOR regulate each other through a negative feed-
forward loop [2]. Therefore, Deptor downregulation
leads to an increase in mTOR activity, which in turn
produces a further reduction of Deptor expression [2].
Deregulation of mTOR is often associated with cancer
pathogenesis, and consistent with its inhibitory effect on
mTOR activity, Deptor levels are frequently low in most
of tumors with few exceptions such multiple myeloma
(MM), thyroid carcinoma or lung cancer, where it is
found to be highly expressed [1]. These findings highlight* Correspondence: valeria.catena@ifo.gov.it; maurizio.fanciulli@ifo.gov.it
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either as an oncogene or as a tumor suppressor. Neverthe-
less, the complete role played by Deptor within cells has
not still been completely elucidated.
In this review, we illustrate the role of Deptor as a nat-
ural mTOR inhibitor, and its activity in controlling sev-
eral molecular pathways, such as apoptosis, cell survival,
autophagy and endoplasmic reticulum (ER) homeostasis.
At the same time, we present a new role of this protein
as a transcriptional activator. Furthermore, we describe
different molecular ways that regulate its expression at
transcriptional and post-transcriptional levels. Finally,
we discuss the role of Deptor in several types of tumors
and highlight it as a novel therapeutic target to improve
the outcome of cancer therapy.An overview of Deptor
Structure of Deptor
Deptor is a monomeric 46 kDa protein encoded by the
DEPTOR gene located on chromosome 8, in a region of
genome, 8q24, rich of several single nucleotide polymor-
phisms (SNPs), and genes involved in general cancer
susceptibility [3].
This protein contains 409 aminoacids and it is charac-
terized by the presence of three highly conservedle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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domains in tandem, respectively of 84 and 75 aminoa-
cids at the N-terminal region (residues 36–119 and
145–219), which are important for membrane associ-
ation of signaling proteins, and a PDZ (Postsynaptic
density 95, Discs large, Zonula occludens-1) domain of
78 aminoacids at the C-terminal region (residues 330–
407), responsible for protein-protein interaction [2, 4]
(Fig. 1). A consensus binding site (designed as Deptor
degron), SSGYFS, recognized by F box βTrCP for its deg-
radation, is located in the linker region between the
C-terminal DEP domain and the PDZ domain. This region
also contains multiple phosphorylation sites, which are in-
volved in regulating this protein functions [2, 5] (Fig. 1).
Deptor gene is found only in vertebrates, sharing an
high homology among several organisms [2] (Fig. 2). At
least two isoforms of human Deptor produced by alter-
native splicing, have been described [6]. The isoform 2
lacks of two in-frame exons in the 5’ coding region (resi-
dues 42–142) and encodes a shorter transcript of 308
aminoacids [6].
Deptor expression and localization
High levels of Deptor protein have been described in
many tissues, such as muscle tissue and salivary
glands, whereas high levels of Deptor mRNA has only
been observed in endocrine glands [7]. At the cellular
level, Deptor shows cytoplasmic, mitochondrial and
nuclear localizations [7–11]. In this regard, the
Deptor nuclear localization has been recently associ-
ated with its role in gene transcription regulation in
MM cells [8].
Deptor biological functions
Deptor is a natural mTOR inhibitor
The functional studies regarding Deptor have been
essentially focused on its important role as a negative
regulator of mTOR kinase activity. Peterson et al. de-
tected Deptor for the first time by mass spectrometry in
HeLa cells, and demonstrated its ability to directly bind
mTOR within mTORC1 and mTORC2 [2]. mTORC1
and mTORC2 are large complexes composed of six and
seven proteins respectively. They share mTOR, mLST8Fig. 1 Structure of Deptor. Schematic illustrating Deptor structure: two DEP dom
the C-terminal DEP domain and PDZ domain, where resides a consensus bindin(mammalian Lethal with Sec-13), Deptor and the Tti1/Tel2
complex [12, 13]. On the contrary, raptor (regulatory-asso-
ciated protein of mammalian target of rapamycin) and
PRAS40 (Proline-Rich Akt Substrate 40 kDa) are specific to
mTORC1, while rictor (rapamycin-insensitive companion
of mTOR), mSin1 (mammalian Stress-activated map
kinase-interacting protein 1) and protor1/2 (protein
observed with rictor 1 and 2) are only part of mTORC2
[12, 13]. These two complexes have different functions
within the cells. Importantly, mTORC1 is able to re-
spond to intra- and extra-cellular inputs, such as
growth factors, oxygen, aminoacids and energy status,
and to promote lipid and protein synthesis, by phos-
phorylating 4EBP1 (eukaryotic translation initiation
factor 4E-Binding Protein 1) and S6K1 (ribosomal
protein S6Kinase beta-1). Moreover, mTORC1 com-
plex inhibits the autophagy process by phosphorylat-
ing and suppressing ULK1 (Unc-51 Like autophagy
activating Kinase 1) activity [14]. mTORC2 is much
less characterized, but it is known that this complex
is involved in cell survival, metabolism and cytoskel-
etal organization [15]. mTORC2 does not respond to
nutrients, but it is sensitive to growth factors like in-
sulin in a PI3K (PhosphatidylInositol-4,5-bisphosphate
3 Kinase)-dependent mechanism [14].
Several findings have showed that Deptor/mTOR
interaction produces a strong inhibition of both
mTORC1 and mTORC2 activity [2]. Moreover,
Deptor and mTOR regulate each other thanks to the
existence of a negative feedback loop, in which
Deptor downregulation results in an increased of
mTOR kinase activity that leads to higher levels of
phosphorylation states of the mTORC1/2 substrates,
S6K1 and Akt [2].
Since mTOR regulates multiple biological processes
involved in mRNA translation, ribosome biogenesis, cell
growth and proliferation, autophagy as well as inflamma-
tion [12], the ability of Deptor to regulate this kinase
have suggested an important role of this protein in the
maintenance of cellular homeostasis. In line with this
notion, the most relevant functions of Deptor are those
involved in proliferation, apoptosis, autophagy, and anti-
inflammation responses.ains and a PDZ domain. Multiple phosphorylation sites are present between
g site, SSGYFS (Deptor degron)
Fig. 2 Structure homology of Deptor. Schematic representation of structural features of human Deptor and its orthologues
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Many findings support the idea of Deptor being a
positive regulator of cell proliferation. As already dem-
onstrated It has been demonstrated that Deptor overex-
pression is able to inhibit mTORC1 leading to an
apparent increase of mTORC2 signaling, inducing Akt
phosphorylation at S437 and T308residues (Fig. 3) [2].
This effect seems to be the consequence of the release
of the negative feedback signal that normally suppresses
PI3K, the major upstream regulator of Akt [2]. PI3K/Akt
pathway is frequently hyper-activated in cancer and the
activation of its downstream targets is associated with
proliferation, differentiation and apoptosis [16]. Indeed,
Akt mediates cell survival directly, by inhibiting
pro-apoptotic proteins, such as caspase-9 and Bad,
and indirectly, by modulating several regulators of cell
death including p53 and Nf-KB [17]. In this scenario,
high levels of Deptor can sustain cell survival in
many cancer cell types.
On the other hand, Deptor has been found to play an
anti-proliferative role in myocytes, where its depletion
resulted in an increase of the rate of proliferation [18].
In particular, myoblasts lacking of Deptor expression
were larger in diameter, exhibiting also increased cell
volume [18]. In addiction, these cells displayed a de-
creased in the percentage of cells in the G1/G0 phase
and concomitantly an increase in the cell number in the
active S-phase (Fig. 4) [18].
Interestingly, recent studies have demonstrated a key
role of Deptor in the embryonic stem cells (ESCs)differentiation, in both mouse and human [19]. Specifically,
high Deptor levels have been found in ESCs, while, they
strongly decrease during cellular differentiation [19]. This
event suggests a role of Deptor in the maintenance of the
pluripotent state of ESCs in association with an increase in
mTORC1 activity [19].
Autophagy
Several studies have reported that Deptor is involved in
the activation of the autophagy pathway (Fig. 3).
Autophagy is a process of self-degradation by which
damaged organelles and misfolded or aggregated pro-
teins are removed by autophagosome degradation [20].
This pathway is important as a barrier to limit tumor
initiation, thanks to its ability to prevent oxidative stress
and genomic instability [21]. Indeed, this process can be
used by cells to balance the sources of energy in re-
sponse to nutrient stress, such as glucose or serum star-
vation [20]. Interestingly, Deptor induces the autophagy
process by suppressing mTOR kinase activity, a well-
known negative regulator of autophagy [5, 22]. In fact,
mTORC1 inhibits autophagosome formation, while
mTORC2 represses the expression of autophagy related
genes (ATG) and other autophagy regulators [23]. In
addition, Deptor accumulation due to depletion of
βTrCP or glucose deprivation, induces an increase in the
level of LC3-II protein and a reduction of p62, well-
known autophagy markers (Fig. 3) [5].
In addition, it has been recently demonstrated that
Deptor stability is promoted by AMBRA1-mediated
Fig. 3 Deptor is a natural mTOR inhibitor. Deptor interacts with and inhibits mTOR kinase activity, leading to the induction of autophagy process.
At the same time, it also activates Akt pathway in order to promote cellular proliferation and survival
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mulation, AMBRA1 establishes a positive feedback loop
reinforcing the inhibition of mTOR activity.
Furthermore, two studies have demonstrated an
increase of Deptor expression in response to autophagy
induction by several kinds of stress [24, 25], and the ex-
istence of a correlation between Deptor gene expression
and autophagy in MM cells [24]. Of interest, Deptor
knockdown has been found associated with a lower ex-
pression of autophagy related proteins, such as ATG5
and LC3, supporting the concept that Deptor is aFig. 4 Deptor depletion is associated with different pathway. The outcome
Deptor expression contributes to proliferation, whereas decreased levels of
caspase 3 or enhancing ER stresspositive regulator of autophagy (Fig. 3) [5, 22]. Never-
theless, the autophagy regulation by Deptor is not
limited to its inhibitory action of mTOR, since a
recent study have revealed that this kinase may not
been directly involved in all steps of this process, be-
ing deregulated in the early stages of autophagy and
then reactivated in the late stages to facilitate the
creation of new lysosomes [26].
An important Deptor role in autophagy has been also
highlighted in an Alzheimer’s disease (AD) model [27].
mTOR dysregulation is implicated in AD, since itsof Deptor depletion depends on cellular context. In myocytes, loss of
Deptor in other tissues mediate the apoptotic response by activating
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neurotoxicity induced by the accumulation of the
β-amyloid peptide aggregates (Aβ) [27]. In normal con-
dition, mTOR acts as a neuroprotective agent by allow-
ing Aβ clearance via autophagosome. Davies et al. have
shown low protein levels of Deptor in precentral gyrus,
postcentral gyrus and occipital lobe of a brain with AD
and in late-onset AD [27]. This Deptor expression re-
duction is responsible for an increased of mTOR kinase
activity resulting in Aβ accumulation. The Aβ in exceed-
ing, in turn, gave rise to a further reduction of Deptor
expression with hyper-activated mTOR ending in
enhanced neurodegenerative process [27].Apoptosis
Deptor is a potent anti-apoptotic agent. Depletion of
Deptor is indeed associated to higher levels of cleaved
caspase-3 and PARP (Poly ADP Ribose Polymerase),
well-known markers of apoptosis induction (Fig. 4) [2].
In particular, the absence of Deptor is sufficient to trig-
ger caspase-dependent apoptosis [17]. Deptor suppres-
sion also induces a reduction in the PI3K/Akt activity,
event that prevents the inhibitory phosphorylation of
pro-caspase-3, thus promoting the apoptotic process
(Fig. 4) [17].
It is still unclear whether this effect on apoptosis is
due to a direct effect of Deptor or whether it is the
result of the inhibition of mTOR kinase activity [24].
Further studies are therefore necessary in order to explore
the existence of some mTOR-independent functions of
Deptor in the apoptotic pathways.Inflammation
Recently, it has been demonstrated that Deptor is a
potent endogenous regulator of endothelial cells (ECs)
responses [28]. ECs activation initiates the acute and
chronic inflammation through promoting local lympho-
cyte responses against cell-mediated immune reaction
[28]. Several endogenous mechanisms are critical for the
prevention of chronic inflammatory diseases and the
speed of resolution determines the outcome of an in-
flammatory reaction. Of note, Deptor has been found
expressed in ECs and its depletion resulted in ECs acti-
vation with induction of several T-cell chemokines and
adhesion molecules [28]. This effect is exerted by affect-
ing mTORC1 signaling, and the activity of ERK1/2 and
STAT1 in these cells [28].
Deptor modulation by pro-inflammatory cytokines has
been also involved in obesity-associated skeletal muscle
inflammation, thus contributing to the onset of insulin
resistance and type 2 diabetes [29]. Therefore, Deptor
activity would be both a mediator (ECs) and a target
(muscle) of inflammatory disorders.Deptor is a transcriptional regulator
Most of the studies investigating Deptor have been pri-
marily focused on its role as inhibitor of mTOR kinase
activity. Interestingly, the nuclear localization of Deptor
in MM cells has been recently observed, leaving to as-
sume that this protein has an additional function in
these cells [8]. In particular, Deptor protein has been
found accumulated onto the chromatin, thus suggesting
its possible involvement in transcriptional regulation.
Consistent with these findings, a RNA-seq analysis of
MM cells depleted for Deptor expression have revealed
approximately 2000 transcripts modulated by this
protein [8]. Gene Ontology analysis of these differentially
expressed genes have shown that Deptor is able to regu-
late several pathways involved in protein localization or
transport, and in particular in ER homeostasis. These
data have been confirmed by the analysis of microarray
public data of MM patients, in which a significant cor-
relation between Deptor and several ER homeostasis
genes, such as ERLIN2, KEAP1, PSEN2 and DERL3, has
been found [8]. Moreover, Deptor has been detected on
specific promoter regions of ER homeostasis genes, thus
confirming its direct involvement in gene transcription
[8]. MM cells are characterized by a high demand of
protein synthesis to produce and secrete large amounts
of immunoglobulins (Igs), thus resulting in high levels of
ER stress [30]. For this reason, MM cells evolved a way
to survive ER stress by activating Unfolded Protein
Response (UPR) [30]. Interestingly, Deptor depletion
produces a further increase in ER stress in MM cells,
thus inducing apoptotic pathway [8]. In particular,
Deptor-depleted MM cells have shown increased UPR
activation, triggering a signaling cascade resulting in ele-
vated apoptosis rate (Fig. 4). Therefore, high levels of
Deptor in MM cells contribute to keeping ER homeosta-
sis under control by inhibiting apoptosis-induced ER
stress [8]. The overall treatment of MM patients is based
on the use of proteasome inhibitor (PI) Bortezomib (Bz),
which is able to activate apoptosis by various ways [31].
Notably, Deptor depletion made MM cells more respon-
sive to cell death induced by Bz treatment [8].
Deptor regulation
Several functional studies have demonstrated that
Deptor expression is subject to a tight regulation exerted
by many mechanisms. Peterson et al. have showed that
both mTORC1 and mTORC2 complexes negatively
regulate Deptor protein and mRNA expression [2].
These findings might explain the inverse correlation be-
tween the high activity of mTORC1/2 complexes and
low levels of Deptor. However, Deptor regulation re-
sulted more complicated, involving post-transcriptional
and transcriptional mechanisms mediated by both com-
plexes. Indeed, it has been demonstrated the existence
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regulation of cell survival and autophagy in response to
environmental changes [5]. In particular, in a low-energy
state, Deptor binds mTOR and inhibits its kinase activ-
ity, whereas in a high-energy state, mTOR rapidly phos-
phorylates Deptor at the βTrCp binding degron,
mediating its degradation by SCF E3 ligase [5, 22, 32].
Specifically, upon serum stimulation, mTOR phosphory-
lates Deptor at S293 and S299 residues promoting in
such way its phosphorylation by S6K1 and RSK1
(Ribosomal S6 Kinase 1) kinase on the three serine resi-
dues (S286, S287, S291) contained in the degron site
(SSGYFS), which becomes recognizable for ßTrCP bind-
ing [5, 22, 32]. ßTrCP is a F-box protein that forms, in
association with SKP1 (S-phase Kinase-associated
Protein 1), cullins, and a RING protein, RBX (RING
BoX protein), the E3 ubiquitin ligase complex SCF
(Skp1-Cul1-F-box) [33].
In addition, another mechanism has been described
illustrating how mTOR can regulate Deptor expression
independently of its phosphorylation [34]. Indeed, in re-
sponse to mitogenic stimulation, Phosphatidic Acid
(PA), generated by PLD1 (PhosphoLipaseD1), binds
mTOR, displacing Deptor from mTORC1, and conse-
quently activating it [34].
Unlike protein stability, which is regulated by phos-
phorylation and consequently ubiquitination by E3
ligase, the transcriptional regulation of Deptor is more
complicated and depends on the cellular context.
In a recent study, Deptor expression has been found
modulated by Che-1/AATF (Che-1) protein in response
to several stress condition [25]. Che-1 is emerging as an
important protein that binds the RNA polymerase II,
and it is involved in a wide range of cellular processes,
such as proliferation, cell cycle control and apoptosis
[35]. Moreover, Che-1 plays an important role in DNA
damage response [36]. For instance, in response to DNA
stress, Che-1 is phosphorylated by ATM/Chk2 kinases
and is recruited on the p53 promoter thus inducing its
expression and the expression of p53-dependent apop-
totic genes [36].
Previous studies have showed that mTOR activity is
subjected to several external stimuli, such as nutrients
and energy sensors [14]. In addition, dysregulation of
the mTOR signaling cascade is associated with many
types of stress, such as DNA damage, glucose or oxygen
deprivation [25]. In agreement with these observations,
it has been demonstrated that upon these kinds of stress,
Che-1 is able to negatively regulate mTOR kinase
activity, by inducing Deptor expression [25]. In particu-
lar, in response to stress, Che-1 is phosphorylated and
recruited onto Deptor promoter, allowing its expression
and leading to mTOR inhibition [25]. In agreement with
a transcriptional regulation of Deptor by Che-1, apositive correlation between these proteins was observed
during MM progression [25].
An analysis of several databases containing transcrip-
tional profiles of human tumors and cancer cell lines
have revealed Deptor downregulation in most cancer
types compared to normal tissue, with the exception of
MM, where this gene has been found upregulated [2].
Many MMs expressing high levels of Deptor are charac-
terized by Ig gene translocation of c-MAF and MAFB
transcription factors, resulting in elevated levels of these
proteins. Deptor has been found to be a direct target of
these factors, and in agreement with this evidence, a
transcriptional profiling study revealed the induction of
Deptor expression by MAFB overexpression. Moreover,
c-MAF depletion produced a reduction of mRNA and
protein levels of Deptor in MM cells [2].
More recently, mechanistic insight on Deptor regula-
tion has been provided in T-cell leukemia (T-ALL),
revealing its crucial role in leukemogenesis [37]. Notably,
in these cells Deptor expression is strongly upregulated
by the oncogene NOTCH1, contributing in such way to
the activation of Akt, a critical effector of the T-ALL
pathogenesis [37]. Deptor and NOTCH1 show a positive
correlation in primary T-ALL samples, and Deptor-
ablated T-ALL cells display a reduction of cellular prolif-
eration and an increase in cell death [37]. However,
prolonged Deptor depletion in these cells results in di-
minished death-promoting effect, suggesting the possi-
bility that T-ALL cells may acquire resistance through
alternative mechanisms [37].
Finally, two transcriptional cofactors, Six4 and Baf60c,
have been found to stimulate Deptor expression by
increasing its transcription in cultured myotubes [29].
In particular, Baf60c in the muscle tissue promotes
glycolytic metabolism by upregulating Deptor expres-
sion [29]. In rodent models of obesity, the expression
of these proteins is reduced because of repressive
epigenetic modifications of their promoters due to
pro-inflammatory cytokines [29]. In line with these
findings, Baf60c/Deptor pathway could be considered
a link between skeletal muscle inflammation and glu-
cose homeostasis in obesity [29].
Deptor and cancer
Deregulation of mTOR signaling is associated with aging
and development of human diseases, including cancer,
obesity, type 2 diabetes and neurodegeneration [14]. In
accordance with these observations, several studies have
highlighted an important role of Deptor in the develop-
ment and in the maintenance of many of these diseases.
Nevertheless, the exact role of Deptor in cancer still
remains controversial, due to its dual behaviour either as
an oncogene or as a tumor-suppressor, depending on
the cellular and tissue context (Table 1).
Table 1 The dual role of Deptor in cancer
Tumor suppressor role Oncogene role





Liver cancer [38] Cervical squamous cell carcinoma
(SCC) [44]
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activated, Deptor levels are much lower than corre-
sponding normal tissue [2]. In colorectal, liver and pan-
creatic cancer [38, 39] and in a subset of tumors like
MM, Deptor mainly acts as a tumor suppressor, since its
loss promotes growth and survival by activating Akt/
mTOR signaling, resulting in phosphorylation of
SGK1 (Serum and Glucocorticoid regulated Kinase 1)
and of its substrate NDRG1 (N-Myc Downstream
Regulated 1) [40, 41].
Deptor has been found to play an important role in
EGFR (Epidermal Growth Factor Receptor)-induced
tumor progression of lung adenocarcinoma and its ex-
pression is significantly reduced in patients with this
type of pathology [11]. In lung adenocarcinoma where
EGFR is overexpressed, low levels of Deptor are ob-
served with a consequent enhanced mTOR kinase activ-
ity. Furthermore, Deptor downregulation leads to tumor
progression and drug resistance. More importantly,
upon treatment with gefitinib, an EGFR tyrosine kinase
inhibitor, it has been observed an increase in Deptor
expression, providing relevant evidence on the im-
portance of Deptor in the development of new thera-
peutic options [11].
A remarkable oncosuppressor role played by Deptor is
observed in the pancreatic ductal adenocarcinoma
(PDAC) [10], where low expression of this protein is de-
tected in pancreatic pre-neoplastic lesions, and gradually
lost in 99% of PDAC tissue. In agreement, ectopic over-
expression of Deptor in these cells blocked cell growth
and apoptotic cell death [10]. It is still unclear what the
exact mechanism is by which these effects are produced.
Probably, Deptor overexpression counteracts the mTOR
activity, but it is also possible that other mechanisms
may play an important role [10]. The evidence that
Deptor loss promotes initiation and progression of pan-
creatic tumorigenesis reinforces this hypothesis [10].
On the contrary, in a specific subset of MM (non-
hyperdiploid type and with c-MAF or MAF-B transloca-
tion) and thyroid carcinoma, Deptor behaves like an
oncogene, as its overexpression results in mTORC1
activity inhibition and a contemporary Akt activation,promoting cancer cells survival [2, 42, 43]. Interestingly,
all these tissues are characterized by a significant protein
production and secretion, resulting in an elevated ER
stress. Therefore, In this context high levels of Deptor
could be required for sustaining ER functions and allow-
ing cell survival.
An oncogenic role of Deptor has also been reported in
cervical squamous cell carcinoma (SCC) where Deptor
overexpression sustains the PI3K/Akt activation required
for cell survival and proliferation [44]. In agreement,
Deptor depletion leads to apoptotic decision in these
cells, through upregulation of p38 MAP kinase, respon-
sible for the activation of apoptosis induced by p53 and
PUMA proteins [44].
Similar findings have been reported in differentiated
thyroid carcinoma (DTC) cell lines and tissues, where
Deptor levels have been found associated with lymph
node status, extra thyroid extension and distant metasta-
sis, confirming its important role in tumor progression
[45]. However, Deptor mRNA did not correlate to pro-
tein levels in these cells, suggesting the presence of post-
transcriptional events controlling Deptor degradation
[45]. In agreement, a strong correlation between Deptor
overexpression and reduced overall survival has been
observed in DTC patients [45].
The role of Deptor in breast cancer however, remains
to be fully elucidated. Indeed, Parvani et al. demon-
strated Deptor dual behaviour during the development
and metastatic progression of triple-negative breast can-
cers (TNBCs) [46]. In particular, low levels of Deptor in
primary tumors are required for the acquisition of EMT
(epithelial mesenchymal transition) and invasive phe-
notypes in association with cell cycle arrest. In stark
contrast, its upregulation in metastatic lesions partici-
pates to the induction of anti-apoptotic and chemore-
sistant activities thanks to its ability to regulate
survivin expression [46].
Deptor as a new attractive molecular target
The findings described above describe an important role
of Deptor in several molecular pathways, often dysregu-
lated in cancer. As already mentioned, Deptor is highly
expressed in some cancer types, such as MM and
T-ALL, and it is associated with poor prognosis and
reduced survival for patients. Consistent with these ob-
servations, Deptor depletion in these cells resulted in
apoptotic cell decision. Therefore, it is conceivable that
the pharmacologically reduction of Deptor may have
therapeutic benefits for the MM treatment in the future.
The studies carried out so far showed how Deptor
depletion could be of help in the improving the outcome
of the MM treatment. In fact, Deptor depletion in com-
bination with different drugs, such as Bz and melphalan,
increases MM cells sensitivity to treatment, promoting
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Deptor over-expression may be considered as a predict-
ive biomarker for therapeutic response in MM patients
treated with thalidomide [48].
In addition, a recent study demonstrated a Deptor in-
volvement in the suppressing effect of metformin on
mTOR signaling and on cell proliferation in human liver
cancer cells [38]. Specifically, metformin treatment leads
to increased Deptor protein levels, by its inhibitory effect
on proteasome activity [38].
Moreover, since Deptor functions are mainly based on
its interaction with mTOR kinase, it is conceivable that
the pharmacological disruption of Deptor-mTOR inter-
action might have therapeutic benefits for MM treat-
ment in the future. In line with this notion, it was
recently demonstrated that MM cells expressing Deptor
are sensitive to NSC12640 [49]. This compound acts by
binding to Deptor at PDZ domain, thus preventing the
interaction with mTOR [49]. The disruption of mTOR-
Deptor interaction allowed the activation of mTORC1/2
complexes and the induction of apoptosis [49]. The
cytotoxicity induced by NSC12640 is directly correlated
with Deptor protein expression, and is mediated by the
activation of mTORC1 and induction of p21 expression.
In agreement, previous studies have revealed that Deptor
knockdown induces p21 expression in a p53 inde-
pendent manner, with a concomitant inhibition of
MM cells growth [50].
As reported in other studies, a rare subtype of mye-
loma, IgD MM, that represents less than 2% of all mye-
loma, is associated with aggressive course, resistance to
chemotherapy and poor outcome [51]. Thanks to the
use of conventional chemotherapy, autologous stem cell
transplantation and the introduction of new drugs, such
as Bz, an increase in overall survival was achieved [51].
Could be of interest to monitor the Deptor protein levels
in this MM isotype and verify whether modulating
Deptor expression it would be possible to improve the
outcome for IgD MM patients.
Nevertheless, further efforts will be necessary to fully
understand the exact mechanism of action of Deptor
and to identify all the pathways implicated in its regula-
tion, in order to unveil new possible anticancer thera-
peutic approaches.Conclusions
As described in this review, Deptor appears to play an
important role in the pathogenesis of many types of can-
cers, mainly through its role in controlling the activity of
mTOR. However, recent studies have also revealed other
its possible functions within the cell, making it even
more important research on how it can become a target
of anticancer therapies.Abbreviations
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